2020
DOI: 10.1016/j.fsi.2020.07.051
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of two adjuvants administrated with a novel hydrogen peroxide-inactivated vaccine against Streptococcus agalactiae in Nile tilapia fingerlings

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
15
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 27 publications
(15 citation statements)
references
References 40 publications
0
15
0
Order By: Relevance
“…Streptococcus agalactiae , a Gram‐positive coccus (round bacterium) (Ramos‐Espinoza et al., 2020), could combine with TLR13 and further activate over‐expression on pro‐inflammatory cytokine (Gao et al., 2021). It induced the outbreak of a serious disease and high mortalities in tilapia in recent years.…”
Section: Discussionmentioning
confidence: 99%
“…Streptococcus agalactiae , a Gram‐positive coccus (round bacterium) (Ramos‐Espinoza et al., 2020), could combine with TLR13 and further activate over‐expression on pro‐inflammatory cytokine (Gao et al., 2021). It induced the outbreak of a serious disease and high mortalities in tilapia in recent years.…”
Section: Discussionmentioning
confidence: 99%
“…S. agalactiae strain (serotype Ib, SA43) isolated from naturally infected Nile tilapia with clinical signs of streptococcosis in the northern region of Paraná State, Brazil, was used in this study (Salvador et al, 2005). The preparation of the S. agalactiae vaccine was described in previous studies (Ramos‐Espinoza, Cueva‐Quiroz, Yunis‐Aguinaga, Alvarez‐Rubio, et al, 2020; Ramos‐Espinoza, Cueva‐Quiroz, Yunis‐Aguinaga, & Moraes, 2020). Briefly, S. agalactiae colonies were grown in Brain Heart Infusion (BHI) broth and incubated in an incubator shaker (C24 Classic Series, New Brunswick Scientific, New Jersey, USA) at 150 rpm, 28°C, for 72 h. Bacterial suspension was treated with H 2 O 2 in order to obtain a final concentration of 5% and incubated at 4°C for 6 h. Then, the bacteria were centrifuged at 10,000 × g , for 10 min, at 4°C, the supernatant discarded and the pellet resuspended in sterile phosphate‐buffered saline (PBS).…”
Section: Methodsmentioning
confidence: 99%
“…Our research group compared the performance of a novel H 2 O 2 ‐inactivated vaccine against S. agalactiae in Nile tilapia with classical formaldehyde‐inactivated vaccine, showing equivalent efficacies (Ramos‐Espinoza, Cueva‐Quiroz, Yunis‐Aguinaga, & Moraes, 2020). In addition, the H 2 O 2 ‐inactivated vaccine showed optimal levels of protection with the inclusion of aluminum hydroxide (relative percent survival [RPS]: 59.3%) and Freund's Incomplete Adjuvant (FIA) (RPS: 77.8%) (Ramos‐Espinoza, Cueva‐Quiroz, Yunis‐Aguinaga, Alvarez‐Rubio, et al, 2020).…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, conjugation with a large immunogenic carrier called an adjuvant is crucial to permit a prolonged antigen release [62]. Different types of adjuvants have been tested for fish vaccines, such as alginate microspheres encapsulated [63], nanoparticle [64], Freund's incomplete adjuvant (FIA) [65], and polysaccharides [66], with promising results. The effect of oral vaccination of killed wholecell S. agalactiae vaccine on stimulating GALTs in tilapia was previously investigated by Firdaus-Nawi et al [67].…”
Section: Development Of a Vaccine Against S Agalactiaementioning
confidence: 99%